Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

devatis ag - lenalidomidum - capsule rigide - lenalidomidum 7.5 mg, lactosum 60.0 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.612 mg, magnesii stearas, kapselhülle: gelatina, titanii dioxidum, e 172 (flavum), drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

devatis ag - lenalidomidum - capsule rigide - lenalidomidum 10.0 mg, lactosum 80.0 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.816 mg, magnesii stearas, kapselhülle: gelatina, e 132, titanii dioxidum, e 172 (flavum), drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

devatis ag - lenalidomidum - capsule rigide - lenalidomidum 15.0 mg, lactosum 120.0 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 1.224 mg, magnesii stearas, kapselhülle: gelatina, e 132, titanii dioxidum, drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

devatis ag - lenalidomidum - capsule rigide - lenalidomidum 20.0 mg, lactosum 160.0 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 1.632 mg, magnesii stearas, kapselhülle: gelatina, e 132, titanii dioxidum, e 172 (flavum), drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

devatis ag - lenalidomidum - capsule rigide - lenalidomidum 25.0 mg, lactosum 200.0 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 2.04 mg, magnesii stearas, kapselhülle: gelatina, titanii dioxidum, drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

accord healthcare s.l.u. - lenalidomide - mieloma multiplo - immunosoppressori - multiple myelomalenalidomide accord as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide accord as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) è indicato per il trattamento di pazienti adulti con mieloma multiplo precedentemente non trattato e che non sono idonei per il trapianto. lenalidomide accordo, in combinazione con desametasone, è indicato per il trattamento del mieloma multiplo in pazienti adulti che hanno ricevuto almeno una precedente terapia. follicular lymphomalenalidomide accord in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Unione Europea - italiano - EMA (European Medicines Agency)

mylan ireland limited - lenalidomide - mieloma multiplo - immunosoppressori - multiple myelomalenalidomide mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. lenalidomide mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide mylan in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1-3a).

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - lenalidomidum - capsule rigide - lenalidomidum 2.5 mg, cellulosum microcristallinum, lactosum 33.2 mg, carmellosum natricum conexum corresp. natrium 0.089 mg, magnesii stearas, kapselhülle: gelatina, titanii dioxidum, e 172 (flavum), e 132, drucktinte: lacca, e 172 (nigrum), propylenglycolum, kalii hydroxidum, pro capsula. - onkologikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - lenalidomidum - capsule rigide - lenalidomidum 5 mg, cellulosum microcristallinum, lactosum 66.4 mg, carmellosum natricum conexum corresp. natrium 0.178 mg, magnesii stearas, kapselhülle: gelatina, titanii dioxidum, drucktinte: lacca, e 172 (nigrum), propylenglycolum, kalii hydroxidum, pro capsula. - onkologikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - lenalidomidum - capsule rigide - lenalidomidum 7.5 mg, cellulosum microcristallinum, lactosum 99.7 mg, carmellosum natricum conexum corresp. natrium 0.266 mg, magnesii stearas, kapselhülle: gelatina, titanii dioxidum, e 172 (flavum), drucktinte: lacca, e 172 (nigrum), propylenglycolum, kalii hydroxidum, pro capsula. - onkologikum - synthetika